Valuation: NeoGenomics, Inc.

Market Cap 2.25B 2.01B 1.85B 1.68B 3.14B 214B 3.2B 22.09B 8.87B 112B 8.44B 8.26B 354B P/E 2026 *
-73.4x
P/E 2027 * -68.5x
Enterprise Value 2.25B 2.01B 1.85B 1.68B 3.14B 214B 3.2B 22.09B 8.87B 112B 8.44B 8.26B 354B EV / Sales 2026 *
2.78x
EV / Sales 2027 * 2.54x
Free-Float
96.13%
Yield 2026 *
-
Yield 2027 * -
1 day-3.07%
1 week+4.76%
1 month-5.34%
3 months+13.67%
6 months+87.69%
Current year+47.79%
1 week 16.61
Extreme 16.61
18.15
1 month 15.41
Extreme 15.41
20.15
Current year 7.06
Extreme 7.065
20.15
1 year 7.06
Extreme 7.065
20.15
3 years 4.72
Extreme 4.72
21.22
5 years 4.72
Extreme 4.72
47.1
10 years 4.72
Extreme 4.72
61.57
Manager TitleAgeSince
Chief Executive Officer 65 2025-03-31
Director of Finance/CFO 57 2026-03-01
President 54 2025-03-31
Director TitleAgeSince
Chairman 64 2021-10-06
Director/Board Member 63 2017-07-18
Director/Board Member 69 2020-07-14
Date Insider Type Main position Quantity % Market Cap. Importance
10/1/26 Exercice

Chairperson

42,035 0.0327%
9/1/26 Tax

General Counsel

-2,692 0.0021%
8/21/26 Exercice

Chairperson

67,272 0.0524%
Change 5-day change 1-year change 3-year change Capi.($)
-3.07%+4.76%+77.89%+23.97% 2.25B
-0.09%-3.44%+15.48%+30.78% 115B
-1.02%+0.89%+2.94%+109.25% 98.85B
-4.98%+2.56%+108.26%+949.66% 59.72B
+1.44%+1.95%-6.04%+93.89% 30.06B
-1.84%+9.86%+42.30%+80.94% 29.34B
-0.43%+4.11%+43.12%+93.56% 27.71B
+0.99%+1.79%+32.33%+408.85% 21.75B
-1.58%+2.35%-18.66%-15.18% 20.66B
-.--%-0.63%-4.85%+30.83% 17.09B
Average -1.06%+2.74%+29.28%+180.65% 42.28B
Weighted average by Cap. -1.06%+1.08%+26.51%+208.14%

Financials

2026 *2027 *
Net sales 808M 724M 666M 603M 1.13B 76.73B 1.15B 7.94B 3.19B 40.36B 3.03B 2.97B 127B 887M 794M 731M 662M 1.24B 84.21B 1.26B 8.71B 3.5B 44.3B 3.33B 3.26B 140B
Net income -31.03M -27.79M -25.56M -23.16M -43.3M -2.95B -44.11M -305M -122M -1.55B -116M -114M -4.89B -34.79M -31.16M -28.66M -25.97M -48.55M -3.3B -49.45M -342M -137M -1.74B -131M -128M -5.48B
Net Debt - -
Projected Income Statement - Annual - NeoGenomics, Inc.
Logo NeoGenomics, Inc.
NeoGenomics, Inc. is a cancer diagnostics company specializing in cancer genetics testing and information services. The Company offers comprehensive oncology-focused testing menus across the cancer continuum, serving oncologists, pathologists, hospital systems, academic centers, and pharmaceutical firms with diagnostic and predictive testing to help them diagnose and treat cancer. Its services include clinical cancer testing, interpretation and consultative services, molecular and NGS testing, comprehensive technical and professional services offering, clinical trials and research, validation laboratory services, and oncology data solutions. It operates a network of laboratories for full-service sample processing and analysis services throughout the United States and a full-service sample-processing laboratory in Cambridge, United Kingdom. Its testing services include Cytogenetics, Fluorescence In-Situ Hybridization (FISH), Flow cytometry, Molecular testing and others.
Employees
2,500
Date Price Change Volume
26-10-30 US$17.38 -3.07% 1,464,370
26-10-29 US$17.93 -0.33% 3,758,970
26-10-28 US$17.99 +4.17% 2,578,609
26-10-27 US$17.27 +3.48% 2,753,351
26-10-26 US$16.69 +0.60% 1,302,439
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
AA
MarketScreener Ratings - NeoGenomics, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
17.38USD
Average target price
23.78USD
Spread / Average Target
+36.81%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - NeoGenomics, Inc.